Fulcrum to merge with Slate Medicines; Slate holders to own ~95% of combined company

Fulcrum Therapeutics, Inc.

Merger values Slate at $350M, Fulcrum at $31.3M; post-close ownership: Slate holders ~55.9%, investors ~39.1%, Fulcrum ~5.0%.
$245M concurrent investment from existing Slate stockholders and new investors; combined cash runway into 2029.
Fulcrum to pay $270M cash dividend to pre-merger Fulcrum stockholders; company renamed Slate Medicines, Inc.
Fulcrum board set at 5 members, all designated by Slate; Fulcrum options with exercise price >$7.00 cancelled at close.
Termination fees: Fulcrum pays $10M, Slate pays $15M; Slate stockholders holding 78.65% support deal.

item 1.01 item 3.02 item 5.01 item 5.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.